Background: MicroRNAs were important regulators of tumors and the expression of miRNA-221 was associated with malignant proliferation and invasion in many tumors. The aim of this study is to explore the expression of miRNA-221 in non-small cell lung cancer (NSCLC) tissues and its correlation with prognosis.
Methods: We retrospectively analyzed the clinical characteristics of 117 NSCLC patients who underwent surgery in our hospital from November 2005 to January 2007. Real-time PCR was used to detect the expression of miRNA-221. Chi-square test was utilized to analyze the relationship between miRNA-221 expression and clinicopathologic features. Survival curves were plotted by using the Kaplan-Meier method and compared by the Log-rank test. A Cox proportional hazard regression model was applied to examine the joint effect of covariants. A P-value less than 0.05 was evaluated as statistically significant.
Results: The patients were divided into two groups according to the relatively expression of miRNA-221. No statistically significance was observed between the expression of miRNA-221 and the clinicopathologic parameters, including gender (χ(2)=0.070, P=0.791), histology (χ(2)=0.414, P=0.520), p-TNM stage (χ(2)=0.068, P=0.794) and history of smoking (χ(2)=0.206, P=0.650). Kaplan-Meier analysis showed that high expression of miRNA-221 was closely associated with a shorter survival time (P<0.001). Finally, both univariate and multivariate analyses demonstrated that high miRNA-221 expression might be a poor prognostic marker of NSCLC patients.
Conclusions: Our results indicated that down-regulation of miRNA-221 was associated with poor prognosis of patients with NSCLC. MiRNA-221 may serve as a molecular prognosis marker for patients with NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019373 | PMC |
| http://dx.doi.org/10.3779/j.issn.1009-3419.2014.03.07 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A comprehensive investigation of identifying miRNA biomarkers and their potential role in age-related cataract by meta-analysis and bioinformatics analysis.
Graefes Arch Clin Exp Ophthalmol
January 2025
Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated People's Hospital of Northwest University, No. 21 Jiefang Road, Xi'an, Shaanxi Province, 710004, China.
Article Synopsis
- Age-related cataract (ARC) is a major cause of blindness, and while surgery is effective, access to care is often limited, necessitating the search for new biomarkers and treatment targets.
- Recent findings suggest that microRNAs (miRNAs) could play a crucial role in the development of ARC and may serve as valuable biomarkers.
- This study identified eight specific miRNAs with altered expression in ARC and explored their potential roles and interactions through bioinformatics, laying the groundwork for further research on their clinical applications.
In vitro and ex vivo screening of microRNA combinations with enhanced cell penetrating peptides to stimulate intervertebral disc regeneration.
JOR Spine
December 2024
Trinity Centre for Biomedical Engineering Trinity Biomedical Sciences Institute, Trinity College Dublin, The University of Dublin Dublin Ireland.
Article Synopsis
- Low back pain is mainly caused by degeneration of the intervertebral disc, prompting research into microRNA (miRNA) therapies which can modulate discogenic factors and inhibit degeneration.
- Nonviral cell penetrating peptides (CPPs) are favored for delivering these miRNAs due to their targeted delivery and low immune response.
- Results showed that dual miRNA delivery significantly enhanced discogenic marker expression and created a regenerative environment, indicating potential benefits for improved treatments for IVD repair.
Mesenchymal Stem Cells and Their Derived Exosomes Mitigated Hepatic Cirrhosis in Rats by Altering the Expression of miR-23b and miR-221.
Iran J Med Sci
November 2024
Department of Medical Biochemistry and Molecular Biology, School of Medicine, Zagazig University, Zagazig, Egypt.
Background: The therapeutic effect of mesenchymal stem cells (MSCs) in liver cirrhosis is limited by their entrapment in the pulmonary vessels. Thus, the use of MSC-derived exosomes has become a promising strategy. The current work aimed to compare the role of human umbilical cord blood-MSCs (hUCB-MSCs) and their derived exosomes in the alleviation of liver cirrhosis focusing on the role of miR-23b and miR-221 and their direct effectors in inflammatory and autophagic pathways.
View Article and Find Full Text PDFGene Expression Aberrations in Alcohol-Associated Hepatocellular Carcinoma.
Int J Mol Sci
September 2024
Division of Molecular Biology, Department of Biology, Faculty of Science, University of Zagreb, 10000 Zagreb, Croatia.
Article Synopsis
- Hepatocellular carcinoma (HCC) is a leading form of liver cancer, commonly stemming from cirrhotic livers due to hepatitis B, hepatitis C, and alcoholism.
- The study focused on the role of miRNA-221 in gene expression related to HCC, particularly comparing its effects in viral versus alcohol-induced cases.
- Results indicated significant differences in gene expression, particularly with one specific gene, highlighting its importance in HCC development and the necessity for varied research methods to understand tumor mechanisms.
Early detection of progressive liver damage in chronic liver disease (CLD) patients is crucial for better treatment response. Several studies have shown the association of microRNA (miRNA) in the progression of CLD in regulating cell proliferation, fibrosis, and apoptosis as well as in carcinogenesis. The study was aimed at determining the expression of miRNA-221 among different stages of fibrosis in CLD patients due to hepatitis B virus (HBV) and nonalcoholic fatty liver disease (NAFLD) and thus evaluate its role as an early biomarker in CLD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!